BIJUVA Drug Patent Profile

Which patents cover Bijuva, and when can generic versions of Bijuva launch?

Bijuva is a drug marketed by Mayne Pharma and is included in one NDA. There are twenty-four patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-four patent family members in twenty-one countries.

The generic ingredient in BIJUVA is estradiol; progesterone. There are seventy-five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the estradiol; progesterone profile page.

DrugPatentWatch^® Generic Entry Outlook for Bijuva

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 21, 2032. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for BIJUVA

International Patents:	174
US Patents:	24
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Drug Prices:	Drug price information for BIJUVA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for BIJUVA
What excipients (inactive ingredients) are in BIJUVA?	BIJUVA excipients list
DailyMed Link:	BIJUVA at DailyMed

See drug prices for BIJUVA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for BIJUVA

NDA:

210132

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BIJUVA

Drug Class	Estrogen Progesterone
Mechanism of Action	Estrogen Receptor Agonists

Paragraph IV (Patent) Challenges for BIJUVA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
BIJUVA	Capsules	estradiol; progesterone	1 mg/100 mg	210132	1	2020-01-06

US Patents and Regulatory Information for BIJUVA

BIJUVA is protected by twenty-four US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-001	Oct 28, 2018		RX	Yes	Yes			Y
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-001	Oct 28, 2018		RX	Yes	Yes
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-001	Oct 28, 2018		RX	Yes	Yes			Y

International Patents for BIJUVA

When does loss-of-exclusivity occur for BIJUVA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Croatia

European Patent Office

France

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Serbia

South Africa

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BIJUVA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	095619	FORMULACIÓN Y TERAPIAS PARA SUSTITUCIÓN HORMONAL DE COMBINACIÓN NATURAL
Argentina	098160	COMPOSICIONES FARMACÉUTICAS DE ESTRADIOL INSERTADAS EN LA VAGINA Y PROCEDIMIENTOS
Argentina	099872	FORMULACIONES DE PROGESTERONA

Supplementary Protection Certificates for BIJUVA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	C300221	Netherlands		PRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
0334429	97C0002	Belgium		PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305
1214076	C01214076/01	Switzerland		PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008

BIJUVA market dynamics and financial trajectory (2025): pricing, volume drivers, channel structure, exclusivity and competitive pressure

Last updated: May 21, 2026

BIJUVA (conjugated estrogens/bazedoxifene capsules) revenue trajectory is defined by (1) menopause/HRT demand, (2) payer steering and step edits, (3) specialty pharmacy distribution and adherence, and (4) exclusivity and competitive entry risk versus other MHT and SERM-based options. Financial performance has tracked with the size of the eligible treated population for vasomotor symptoms plus postmenopausal symptoms and with the extent to which formulary access has held across major commercial plans and Medicare Part D during the product’s branded life.

What is BIJUVA (conjugated estrogens and bazedoxifene) and how does it compete in menopause MHT?

Featured snippet: BIJUVA is an oral combination hormone therapy using conjugated estrogens plus bazedoxifene, positioned for vasomotor symptom relief and prevention of postmenopausal osteoporosis while aiming to reduce risks associated with endometrial stimulation via SERM activity.
It competes against single-agent estrogen approaches (with or without progestin depending on regimen), SERM and tissue-selective estrogen complex strategies, and non-hormonal therapies. Market share is driven by payer preference for fixed combinations, dosing simplicity, and formulary tier placement rather than by differentiation in clinical outcomes alone.

Menopause indications and payer decision logic

Payer coverage typically evaluates:

• Eligibility and symptom category for vasomotor symptoms (VMS).
• Need for osteoporosis risk reduction.
• Endometrial risk management assumptions and regimen complexity.
• Total cost of therapy versus alternative branded/generic combinations.

Competitive set (commercial dynamics)

BIJUVA’s real-world competitive perimeter typically includes:

• Other estrogen-based MHT regimens (including alternatives that avoid progestin through different product mechanics).
• SERM-based therapies and estrogen/SERM hybrids.
• Non-hormonal options where formularies have steered due to risk profile, age bands, or preference for avoidance of hormone therapy.

What market dynamics drive BIJUVA demand: guideline adoption, adherence, and payer steering?

Featured snippet: BIJUVA demand is most sensitive to formulary access, formulary tier position, and adherence, with switching driven by coverage changes and patient tolerability.
Unlike injectables or high-frequency dosing drugs, BIJUVA is an oral, chronic therapy where access and refill behavior explain a large share of near-to-mid term sales variance.

1) Formulary access and pharmacy benefit design

Key dynamics:

• Step edits: plans may require failure or intolerance to alternative estrogen regimens first.
• Prior authorization: triggered by age, diagnosis codes, or therapy line history.
• Quantity limits: less common for oral daily therapies but can appear in budget-driven formulary redesigns.
• Tier placement: movement from preferred to non-preferred tiers compresses net price via higher patient cost share.

2) Prescriber behavior and switching

Prescribers often switch when:

• Patient experiences side effects tied to estrogen-related effects.
• Coverage changes make a different regimen cheaper under plan design.
• Patient’s risk profile shifts, changing perceived suitability of HRT.

3) Adherence and discontinuation

BIJUVA’s revenue is exposed to:

• Early discontinuation in VMS, where symptom improvement can reduce persistence once hot flashes abate.
• Longer persistence among patients continuing bone health goals, especially where osteoporosis risk is monitored.

4) Real-world risk perception

Even with label-specific positioning, MHT class risk perception can move demand through media and clinician risk tolerance. That effect is usually transmitted through payer coverage and patient acceptance rather than through day-to-day clinical practice alone.

How has BIJUVA’s financial trajectory evolved: pricing, net sales, and channel mix?

Featured snippet: BIJUVA’s financial trajectory has been shaped by branded net pricing, volume growth tied to formulary access, and periodic payer tightening as HRT budgets face rising utilization costs.
Branded menopause therapies generally show a pattern:

• Initial penetration and growth when new-to-market demand aligns with aggressive coverage.
• Mid-cycle stabilization as plans consolidate MHT positions into a smaller set of preferred agents.
• Late-cycle compression when higher rebates, tighter PA, or substitutes gain preferred status.

Net price and rebate exposure

For branded MHT products:

• Rebate and discount intensity usually rises after initial uptake as payers renegotiate.
• Net sales can lag gross list price if rebate intensity increases or if patient cost share rises.

Channel mix: retail vs specialty

BIJUVA is typically dispensed through retail and specialty in the US depending on payer mechanics. Financial outcomes are sensitive to:

• Whether plans route to particular pharmacy networks.
• Patient out-of-pocket costs impacting fill rates.
• Pharmacy benefit manager (PBM) contract structures affecting dispensing volume and conversion.

Revenue inflection points to track

BIJUVA’s financial trajectory generally turns around:

• Formulary inclusion changes (preferred vs non-preferred).
• Medicare Part D redesigns and annual formulary cycles.
• Any generics or alternative branded entrants that alter “default” prescribing.

When does BIJUVA lose exclusivity and what entry risks does that create for generic or alternative competitors?

Featured snippet: BIJUVA exclusivity and patent protection determine the timing of any generic entry risk; market impact is usually visible as plans pre-position substitute access before the first-to-market launch.
For menopause combinations, competitive threats often arrive via:

• Generic versions of one or both components if feasible through FDA pathway and patent landscape.
• Authorized generics if the brand owner leverages settlement or licensing strategies.
• Switch to competing branded regimens when generic access is delayed but formulary preference changes.

Patent and exclusivity-driven market timing

Market effect typically occurs in two waves:

1. Pre-launch: payer substitution for new scripts, formulary switches, and prior authorization tightening.
2. Launch: fill-rate changes and new prescriptions shifting to lower-cost alternatives.

Litigation and Paragraph IV risk (how it hits sales)

If a generic is pursued through a Hatch-Waxman pathway:

• Settlement terms can create a “launch cliff” or delayed entry.
• Court timelines can be volatile and alter PBM behavior before launch.

What is the Orange Book status of BIJUVA and how many patents cover it?

Featured snippet: Orange Book listings define the patent estate that governs entry risk; the number and type of listed patents (drug substance, drug product, formulation, and method-of-use) determines launch barriers.
BIJUVA’s Orange Book profile would be the primary map for:

• Generic applicability.
• Likely design-around options.
• Which patents trigger Paragraph IV certification in an ANDA filing (if pursued).

How to read patent coverage for market impact

For combination products, market risk often comes from:

• Product-specific formulation patents.
• Method-of-use or dosing regimen patents that can block generic labeling entry even if components are off-patent.
• Drug substance patents that block entry on the active ingredient.

(No Orange Book patent list is included here because the request requires itemized, verifiable Orange Book data and the necessary listing is not provided in the prompt.)

What patent estate strength questions matter most for BIJUVA’s competitive position?

Featured snippet: Patent estate strength is the practical determinant of when lower-cost competition can label-match BIJUVA, not just when it can sell “close substitutes.”
For the business impact of an IP wall, focus is on:

• How many patents remain in force at expected ANDA or 505(b)(2) filing windows.
• Whether key patents are composition, formulation, or method-of-use.
• Whether the remaining patents are likely to survive litigation based on historical case outcomes in the relevant jurisdiction.

Which patent categories usually block entry the longest

• Formulation and drug product patents: delay ANDA if the product cannot be replicated within patent constraints.
• Method-of-use: block label-linked substitution even if the molecule is accessible.
• Combination-related patents: can require both actives to be tied to the protected configuration.

How do competing menopause therapies compare with BIJUVA on payer fit and uptake?

Featured snippet: BIJUVA’s payer fit depends on plan preferences for hormone therapy regimens that meet symptom control plus bone health goals while minimizing perceived safety and administrative friction.
In practice, comparisons among menopause therapies usually hinge on:

• Net cost and rebate structures.
• Prior authorization burden and documentation requirements.
• Patient out-of-pocket costs by plan tier.
• Dosing schedule simplicity and switching friction.

Switching dynamics

• If a competitor is preferred and BIJUVA moves to non-preferred status, net sales can compress quickly even without clinical failure.
• If a competitor has broader label coverage or easier initiation criteria, prescribers can shift.

What generic entry scenarios could hit BIJUVA first, and how would they play out commercially?

Featured snippet: The earliest commercially meaningful threat is usually a label-linked substitute that is preferred by payers and can be adopted quickly by prescribers.
Common scenarios:

• Partial generic substitutes: disrupt pricing but may not fully convert patients if label matching is weaker.
• Full combination entry: drives deeper substitution if the competitor is formulary-preferred and has comparable utilization criteria.
• Delayed competition: if patent walls hold, payers may still reduce BIJUVA exposure through utilization management.

Launch-phase metrics to watch

Commercial hit timing is typically observable through:

• New-to-therapy script share declines.
• Higher PA denials or increased denials for BIJUVA.
• Reduced refill persistence as prescribers shift.

What FDA and reimbursement dynamics affect BIJUVA adoption in the US?

Featured snippet: FDA labeling alone does not determine market outcomes; US reimbursement design determines whether clinicians can initiate and continue BIJUVA without administrative or cost barriers.
Key factors:

• Medicare Part D formulary inclusion and formulary tiering.
• Commercial PBM contract strategy.
• Prior authorization requirements tied to diagnosis or line of therapy.

Which companies are most exposed to BIJUVA competitive displacement?

Featured snippet: Competitive exposure concentrates among manufacturers of preferred MHT regimens and any sponsors pursuing lower-cost equivalents that can displace BIJUVA through formulary placement.
Without a provided BIJUVA-specific competitor/IP dataset, the robust way to assess exposure is to map:

• The top branded competitors in VMS and bone-risk aligned regimens.
• The sponsors of generic or hybrid therapies likely to gain preferred status post-expiry.

(No company list is provided because the required BIJUVA-specific competitive map, including ORANGE BOOK/ANDA/PIVOTAL litigation and competitor product positioning, is not supplied in the prompt.)

Key takeaways

• BIJUVA’s financial trajectory is primarily a function of formulary access, payer steering (tiering, PA), and adherence persistence rather than pure market growth.
• The biggest near- to mid-term sales driver is how PBMs manage switching among menopause MHT regimens and how net pricing evolves with rebate intensity.
• Patent exclusivity timelines and Orange Book patent coverage determine the earliest generic or alternative entry risk; market impact typically begins with payer pre-positioning even before a launch.
• For financial modeling, the leading indicators are new prescription share, formulary tier shifts, PA approval rates, persistence, and Medicare Part D redesign outcomes.

FAQs

1. How do Medicare Part D formulary changes usually affect branded menopause therapies like BIJUVA?
2. What metrics best predict BIJUVA sales declines during late-cycle payer tightening?
3. How does net price compression typically evolve for oral branded MHT combinations under US PBM renegotiations?
4. What combination-therapy patent categories create the highest generic launch barriers for products like BIJUVA?
5. How do settling strategies in Hatch-Waxman cases change the timing of competitive entry for branded MHT drugs?

References (APA)

1. FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” U.S. Food and Drug Administration.
2. Hatch-Waxman. Food and Drug Administration and associated guidance materials on ANDA/505(b)(2) exclusivity and patent certification frameworks.

DrugChatter Q&A for BIJUVA

Is there a generic for bijuva?
Bijuva france commercialisation?
Can Bijuva be used for hot flashes?